Home - Products - Angiogenesis - VEGFR - UNC0064-12 hydrochloride (1430089-64-7(free base))

UNC0064-12 hydrochloride (1430089-64-7(free base))

CAS No. ——

UNC0064-12 hydrochloride (1430089-64-7(free base))( —— )

Catalog No. M22768 CAS No. ——

UNC0064-12 hydrochloride is an inhibitor of VEGFR2 extracted from patent WO2013055780A1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 357 In Stock
10MG 597 In Stock
25MG 882 In Stock
50MG 1350 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    UNC0064-12 hydrochloride (1430089-64-7(free base))
  • Note
    Research use only, not for human use.
  • Brief Description
    UNC0064-12 hydrochloride is an inhibitor of VEGFR2 extracted from patent WO2013055780A1.
  • Description
    UNC0064-12 hydrochloride is an inhibitor of VEGFR2 extracted from patent WO2013055780A1.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    400.91
  • Molecular Formula
    C19H25ClN8
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.NCCCNc1ccc(Nc2nccc(Nc3cc([nH]n3)C3CC3)n2)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. MULTIPLEXED KINASE INHIBITOR BEADS AND USES THEREOF. Patent Application WO/2013/055780 Kind Code: A1
molnova catalog
related products
  • TG 100572 Hydrochlor...

    TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases.

  • PKI-166

    PKI-166 is an oral inhibitor of EGF-R tyrosine kinase (IC50:0.7 nM) that is both effective and selective. PKI-166 can effectively inhibit the growth and metastasis of various human cancer cells including pancreatic cancer.

  • Fruquintinib

    A potent and highly selective small molecule inhibitor of VEGFR1/2/3 with IC50 of 33/3/5/0.5 nM, respectively.